#161787

OV-4453 cell line

Cat. #161787

OV-4453 cell line

Cat. #: 161787

Organism: Human

Tissue: Derived from ascites from patient with high grade serous carcinoma

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: OV-4453 cell line
  • Alternate name: OV-4453
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from ascites from patient with high grade serous carcinoma
  • Donor: Age of diagnosis: 70; BRCA hereditary status: BRCA2(+); Stage IIIC; Mutations: BRCA2, TP53, CSMD2, RB1; Pre-treatment
  • Morphology: Formed numerous individual small aggregates
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious ascites from patient that had no chemotherapy prior to surgery. Patient received radiotherapy and hormonotherapy for breast cancer five year prior to ovarian cancer diagnosis.
  • Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
  • Additional notes: Patient 4453 was age 70 at diagnosis, BRCA hereditary status was BRCA2(+), and had previous history of breast cancer. Treatment for ovarian cancer included Carboplatin/taxol and interval surgery. Year of sampling was 2009.

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Vias et al. 2023. Elife. 11
  • 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16
  • 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30
  • 15(9):2566. PMID: 37174032